1936 related articles for article (PubMed ID: 34311539)
1. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
2. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
[TBL] [Abstract][Full Text] [Related]
3. Black tea bioactives as inhibitors of multiple targets of SARS-CoV-2 (3CLpro, PLpro and RdRp): a virtual screening and molecular dynamic simulation study.
Gogoi M; Borkotoky M; Borchetia S; Chowdhury P; Mahanta S; Barooah AK
J Biomol Struct Dyn; 2022 Sep; 40(15):7143-7166. PubMed ID: 33715595
[TBL] [Abstract][Full Text] [Related]
4. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays.
Gupta Y; Maciorowski D; Zak SE; Jones KA; Kathayat RS; Azizi SA; Mathur R; Pearce CM; Ilc DJ; Husein H; Herbert AS; Bharti A; Rathi B; Durvasula R; Becker DP; Dickinson BC; Dye JM; Kempaiah P
Methods; 2021 Nov; 195():57-71. PubMed ID: 33453392
[TBL] [Abstract][Full Text] [Related]
5. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents.
Mody V; Ho J; Wills S; Mawri A; Lawson L; Ebert MCCJC; Fortin GM; Rayalam S; Taval S
Commun Biol; 2021 Jan; 4(1):93. PubMed ID: 33473151
[TBL] [Abstract][Full Text] [Related]
6. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors.
Chiou WC; Hsu MS; Chen YT; Yang JM; Tsay YG; Huang HC; Huang C
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):147-153. PubMed ID: 33430659
[TBL] [Abstract][Full Text] [Related]
7. Computational drug repurposing study of antiviral drugs against main protease, RNA polymerase, and spike proteins of SARS-CoV-2 using molecular docking method.
Jalalvand A; Khatouni SB; Najafi ZB; Fatahinia F; Ismailzadeh N; Farahmand B
J Basic Clin Physiol Pharmacol; 2021 Jul; 33(1):85-95. PubMed ID: 34265888
[TBL] [Abstract][Full Text] [Related]
8. In silico prediction of SARS-CoV-2 main protease and polymerase inhibitors: 3D-Pharmacophore modelling.
Mosayebnia M; Hajiagha Bozorgi A; Rezaeianpour M; Kobarfard F
J Biomol Struct Dyn; 2022 Sep; 40(14):6569-6586. PubMed ID: 33599180
[TBL] [Abstract][Full Text] [Related]
9. Identification of repurposing therapeutics toward SARS-CoV-2 main protease by virtual screening.
Sanachai K; Somboon T; Wilasluck P; Deetanya P; Wolschann P; Langer T; Lee VS; Wangkanont K; Rungrotmongkol T; Hannongbua S
PLoS One; 2022; 17(6):e0269563. PubMed ID: 35771802
[TBL] [Abstract][Full Text] [Related]
10. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
[TBL] [Abstract][Full Text] [Related]
11. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
[TBL] [Abstract][Full Text] [Related]
12. Tomatidine and Patchouli Alcohol as Inhibitors of SARS-CoV-2 Enzymes (3CLpro, PLpro and NSP15) by Molecular Docking and Molecular Dynamics Simulations.
Zrieq R; Ahmad I; Snoussi M; Noumi E; Iriti M; Algahtani FD; Patel H; Saeed M; Tasleem M; Sulaiman S; Aouadi K; Kadri A
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639036
[TBL] [Abstract][Full Text] [Related]
13. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL
Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ
Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of potential anti-RNA-dependent RNA polymerase (RdRP) drugs against the newly emerged model of COVID-19 RdRP using computational methods.
Poustforoosh A; Hashemipour H; Tüzün B; Pardakhty A; Mehrabani M; Nematollahi MH
Biophys Chem; 2021 May; 272():106564. PubMed ID: 33711743
[TBL] [Abstract][Full Text] [Related]
15. Flavonoid glycosides and their putative human metabolites as potential inhibitors of the SARS-CoV-2 main protease (Mpro) and RNA-dependent RNA polymerase (RdRp).
da Silva FMA; da Silva KPA; de Oliveira LPM; Costa EV; Koolen HH; Pinheiro MLB; de Souza AQL; de Souza ADL
Mem Inst Oswaldo Cruz; 2020; 115():e200207. PubMed ID: 33027419
[TBL] [Abstract][Full Text] [Related]
16. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.
Rai H; Barik A; Singh YP; Suresh A; Singh L; Singh G; Nayak UY; Dubey VK; Modi G
Mol Divers; 2021 Aug; 25(3):1905-1927. PubMed ID: 33582935
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel inhibitors of SARS-CoV-2 main protease (M
Verma S; Patel CN; Chandra M
J Comput Chem; 2021 Oct; 42(26):1861-1872. PubMed ID: 34287986
[TBL] [Abstract][Full Text] [Related]
18. Targeting 3CLpro and SARS-CoV-2 RdRp by
Shady NH; Hayallah AM; Mohamed MFA; Ghoneim MM; Chilingaryan G; Al-Sanea MM; Fouad MA; Kamel MS; Abdelmohsen UR
Molecules; 2021 Jun; 26(12):. PubMed ID: 34205768
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and Identification of Novel Potential Molecules Against COVID-19 Main Protease Through Structure-Guided Virtual Screening Approach.
El Bakri Y; Anouar EH; Ahmad S; Nassar AA; Taha ML; Mague JT; El Ghayati L; Essassi EM
Appl Biochem Biotechnol; 2021 Nov; 193(11):3602-3623. PubMed ID: 34324152
[TBL] [Abstract][Full Text] [Related]
20. Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study.
Tan Q; Duan L; Ma Y; Wu F; Huang Q; Mao K; Xiao W; Xia H; Zhang S; Zhou E; Ma P; Song S; Li Y; Zhao Z; Sun Y; Li Z; Geng W; Yin Z; Jin Y
Bioorg Chem; 2020 Nov; 104():104257. PubMed ID: 32927129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]